Original title: Caution before canonisation: a clinical and implementation science perspective on psychedelics
Some early trials suggest that psilocybin and MDMA, given alongside structured therapy, can quickly ease symptoms. But many studies have few participants and do not follow them for long, so we cannot yet tell how lasting the benefits are or how well they apply to everyday care. The paper argues that promise in controlled trials is not the same as readiness for broad use. Researchers still need stronger evidence about safety, lasting effects, comparisons with other treatments, and how care would work outside trials.
Imagine trying a new recipe at a small dinner party. A few guests like it, but you have not checked whether they still like it later or whether it works for people with different tastes. In this paper, the dinner party stands for an early controlled trial, and serving the recipe to a much larger crowd stands for routine clinical use. The authors say more testing is needed before that wider step.
People seeking help for depression, post-traumatic stress disorder, or substance use disorders need treatments that are not only promising in trials but also safe and effective in everyday care. This paper explains why small studies and short follow-up leave important questions unanswered.
The paper does not establish that psychedelic therapies are ineffective, nor does it provide new trial results. Its central point is that current evidence is limited by small samples, short follow-up, functional unblinding, and uneven safety reporting. The abstract does not specify which future study designs or implementation plans should be used.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Caution before canonisation: a clinical and implementation science perspective on psychedelics — Andreas Paris, Foteïni Thoma, Aikaterini Velentza et al. — Frontiers in Psychiatry — doi:10.3389/fpsyt.2026.1922928
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper.